공시 • Mar 25
Item 9 Labs Corp. Declines Re-Election of Lisa Rejler as Board Member Item 9 Labs Corp. announced that the Nomination Committee proposes that the Annual General Meeting shall re-elect the board members Peter Rejler, Jan Samuelsson, Patrik Boman, Peter Johansson and Susanne Blanke and that the General Meeting resolves on new election of Martina Rejler. The board member Lisa Rejler declines re-election, at the AGM to be held on April 24, 2025. 공시 • Apr 11
Item 9 Labs Corp., Annual General Meeting, May 16, 2024 Item 9 Labs Corp., Annual General Meeting, May 16, 2024, at 14:00 Central European Standard Time. Location: Östra Hamngatan 52 Gothenburg Sweden Agenda: To consider Presentation of the annual financial report and the auditor's report, as well as the consolidated annual financial report, the consolidated auditor's report and the Board of Directors' report; to consider (a) the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet as well as the Board of Directors report pursuant to Chapter 8, Section 53a of the Swedish Companies Act, (b) the disposition of the Company's funds according to the adopted balance sheet and (c) the discharge from liability for the members of the Board of Directors and the CEO; to consider the election of members of the Board of Directors and appointment of auditors and deputy auditors, if any; and to consider any other matters. 공시 • May 25
Item 9 Labs Corp. Announces Management Changes Item 9 Labs Corp. announced that Director Jeffrey Rassás has been appointed to Strategic Advisor and will be primarily driving investor & public relations as well as capital needs. Chris Wolven, current Chief Operating Officer, will now oversee all Company entities and operations and will be the primary Company-facing executive for Item 9 Labs Corp. Michael Keskey has resigned as Chief Legal Officer. 공시 • May 16
Item 9 Labs Corp. announced delayed 10-Q filing On 05/15/2023, Item 9 Labs Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 11
Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-Rolls Item 9 Labs announced the latest release of its limited edition one-gram rosin-infused pre-rolls in participating Arizona dispensaries. The product release follows a successful initial test run in December 2022 that immediately sold out after being stocked in local dispensaries and generated extremely positive customer and budtender feedback on the product quality. The demand for solventless cannabis products in Arizona has continued to grow since the start of the state's adult-use cannabis market, especially in the concentrate and vape categories. The niche sector provides a consistent, high quality and fuller expression of the various cannabinoids and terpenes that the cannabis plant has to offer. Cannabis data firm BDSA analyzed product data from the past year and noted that the growing rosin category is making a significant mark among many mature markets in the evolving industry, counting single to double-digit growth in sales from 2021 to 2022. Item 9 Labs' addition of rosin-infused pre therolls bolsters its already extensive product lineup of connoisseur grade pre-rolls, featuring one-gram pre-rolls crafted with its award-winning flower and infused with live resin sugar, live resin badder or crumble concentrates. According to BDSA's most recent market research, Item 9 Labs ranked No. 3 in Arizona's one-gram infused pre-roll category for February 2023, capturing 8.5% market share. Overall, the state generated $4.16 million in infused pre-rolls that month. Being sold in over 65% of Arizona's dispensaries, Item 9 Labs is recognized as one of the top 10 leading cannabis brands in the state. The rosin-infused pre -infused pre-rolls are sold at participating Botanica, JARS and Nature's Medicines locations, among other dispensaries throughout Phoenix. 공시 • Dec 30
Item 9 Labs Corp. announced delayed annual 10-K filing On 12/29/2022, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Dec 09
Item 9 Labs Corp. Announces Management Promotions Item 9 Labs Corp. announced promotion of Mark Busch, Senior Vice President of Corporate Development, Cory Carter, Senior Vice President of Cultivation and Jayne Levy Senior Vice President of Communications. Mark Busch is One of the first hires on the Unity Rd. brand, Busch joined in 2018, pre-dating Item 9 Labs Corp.'s acquisition of Unity Rd.'s franchisor, OCG Inc. in 2021. He is responsible for overseeing merger and acquisition strategy and activities. He has led the team through acquisitions of multiple dispensaries and most recently, has been spearheading the Company's approaching acquisition of Sessions. Carter joined OCG Inc. in 2019 and took over all Item 9 Labs Corp. cultivation operations upon acquisition close. He is lead on all production, manufacturing and packaging of the Company's award-winning Item 9 Labs cannabis products, including managing a team of 50-plus and aiding in the continued development of the Company's cultivation and lab site in Coolidge, Ariz. Levy has been with Unity Rd. since the cannabis franchise's inception in 2018. She plays an integral role in the Company with a hand in all facets of communications – spearheading internal and corporate communications, investor relations, public relations and beyond. 공시 • Aug 04
Item 9 Labs Corp. to Report Q3, 2022 Results on Aug 15, 2022 Item 9 Labs Corp. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 15, 2022 공시 • Jun 05
Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy Officer On June 1, 2022, Mr. Jeffrey Rassas resigned, effective immediately, as the Chief Strategy Officer of Item 9 Labs Corp. (the Company") and the Company's management accepted Mr. Rassas' resignation on June 1, 2022. Mr. Rassas' resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, practices, or otherwise. Mr. Rassas will remain on the Company's board of directors and will continue working with the Company in a consulting role. 공시 • May 26
Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million. Item 9 Labs Corp. (OTCPK:INLB) signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million on May 18, 2022. As per the terms of the transaction, Item 9 Labs shall pay $12.8 million plus the earnout payments of $4.1 million of common stock 12 months following the closing date and $4.1 million common stock 24 months following the closing date subject to post-closing adjustments. Item 9 Labs Corp. shall pay a termination fee of $0.54 million to the sellers. The transaction is subject to customary closing conditions including Item 9 Labs receiving financing sufficient to complete the transaction and Sessions Cannabis shall have a minimum cash balance of $0.1 million. Frank Robinson and Jeffrey Mikelberg of Cassels Brock & Blackwell LLP acted as legal advisors to the sellers and Francesco Gucciardo and Gary Volman of Aird & Berlis LLP acted as legal advisor to Item 9 Labs Corp. 공시 • Mar 06
Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC. Item 9 Labs Corp. (OTCPK:INLB) agreed to acquire Certain Assets of Nebrina Adams County LLC for $2 million on October 6, 2021. The total purchase price will be payable as follows: (i) Upon conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars. ii) At the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following the Closing Date (the " Note " or " Promissory Note" ) until paid in full; and (iii) Buyer shall issue to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject to a leak out agreement. Closing shall be contingent upon the unconditional approval by MED and the Local Licensing Authority of the Transactions. Jean Gonnell of Gonnell Law acted as legal advisor to Nebrina. Zuber Lawler & Del Duca LLP acted as legal advisor to Item 9.
Item 9 Labs Corp. (OTCPK:INLB) acquired Certain Assets from Nebrina Adams County LLC on March 4, 2022. 공시 • Mar 04
Item 9 Labs Corp. Appoints Shane Evans to Its Board of Directors Item 9 Labs Corp. announced that Shane Evans, founder of Massage Heights, has been appointed to its Board of Directors. 공시 • Feb 03
Item 9 Labs Corp. Announces Resignation of Ronald L. Miller, Jr. from the Board of Directors On January 25, 2022, Mr. Ronald L. Miller, Jr. resigned, effective immediately, from the board of directors of Item 9 Labs Corp. and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role. 공시 • Dec 31
Item 9 Labs Corp. announced delayed annual 10-K filing On 12/30/2021, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Dec 30
Item 9 Labs Corp. announced delayed annual 10-K filing On 12/29/2020, Item 9 Labs Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Sep 26
Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million. Item 9 Labs Corp. (OTCPK:INLB) entered into an agreement to acquire OCG Inc. for $36.6 million on February 27, 2020. Under the terms of the transaction, Item 9 Labs Corp. will issue 30 million restricted shares as consideration to acquire 52.22 million shares of OCG Inc. resulting in an exchange ratio of 0.575 shares of Item 9 Labs Corp. for each share of OCG Inc. Upon closing, OCG Inc. will become a wholly-owned direct subsidiary of Item 9 Labs Corp. Upon closing of the transaction, OCG Inc. may nominate, and Item 9 Labs Corp. agrees to appoint, two persons designated by OCG Inc. to Item 9 Labs Corp.’s Board of Directors. The transaction is subject to the adoption of the agreement by the requisite vote of the stockholders of OCG Inc. and Item 9 Labs Corp., approval of the issuance of shares of Item 9 Labs Corp. as merger consideration, an appropriate level and Director and Officers Liability Insurance being in place, financing contingency that Item 9 Labs Corp. must raise approximately $2 million and delivery by OCG Inc. of copies of a lock up and leak out agreement. The Board of Directors of Item 9 Labs Corp. has approved the agreement and the transactions contemplated hereby. The transaction is expected to closing in early July 2020. The transaction is expected to close near the Item 9 Labs’s fiscal year end of September 30, 2020. Michael Weiner and David Mangum of Dorsey & Whitney LLP acted as legal advisors for OCG, Inc. Jessica M. Lockett of Horwitz +Armstrong acted as legal advisor for Item 9 Labs Corp.